Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation.

[1]  E. Fosse,et al.  Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.

[2]  J. Weiler,et al.  Cytokine and complement levels in patients undergoing cardiopulmonary bypass. , 1993, The Journal of thoracic and cardiovascular surgery.

[3]  W. van Oeveren,et al.  Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[4]  W. Baumgartner,et al.  Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[5]  J. Svennevig,et al.  Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits. , 1993, The Journal of thoracic and cardiovascular surgery.

[6]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[7]  M. Turina,et al.  Reduction and elimination of systemic heparinization during cardiopulmonary bypass. , 1992, The Journal of thoracic and cardiovascular surgery.

[8]  H. Hansson,et al.  Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. , 1992, Scandinavian journal of thoracic and cardiovascular surgery.

[9]  P. Venge,et al.  Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass. , 2008, Artificial organs.

[10]  E. Fosse,et al.  Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials. , 2008, Clinical and experimental immunology.

[11]  M. Abdelnoor,et al.  Conventional blood conservation techniques in 500 consecutive coronary artery bypass operations. , 1991, The Annals of thoracic surgery.

[12]  L. Hsu.  Principles of heparin-coating techniques , 1991 .

[13]  V. Videm,et al.  Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. , 1991, The Journal of thoracic and cardiovascular surgery.

[14]  H. Lindberg,et al.  Systemic and pulmonary circulatory effects of protamine following cardiopulmonary bypass in man. , 1991, Scandinavian journal of thoracic and cardiovascular surgery.

[15]  S Senn,et al.  Analysis of serial measurements in medical research. , 1990, BMJ.

[16]  E. Ritz,et al.  Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. , 1990, Kidney international.

[17]  P. Venge,et al.  Inflammatory system activation during cardiopulmonary bypass as an indicator of biocompatibility: a randomized comparison of bubble and membrane oxygenators. , 1990, Scandinavian journal of thoracic and cardiovascular surgery.

[18]  W. Hörl,et al.  Plasma levels of main granulocyte components during cardiopulmonary bypass. , 1988, Journal of Thoracic and Cardiovascular Surgery.

[19]  T. Lea,et al.  Quantification in Enzyme‐Linked Immunosorbent Assay of a C3 Neoepitope Expressed on Activated Human Complement Factor C3 , 1988, Scandinavian journal of immunology.

[20]  P. Venge,et al.  Serum and plasma measurements of neutrophil granule proteins during cardiopulmonary bypass: A model to estimate human turnover of lactoferrin and myeloperoxidase , 1987, European journal of haematology.

[21]  A. Cheung,et al.  Cardiopulmonary effects of cuprophane-activated plasma in the swine. , 1986, Kidney international.

[22]  S. Frøland,et al.  Quantification of the Terminal Complement Complex in Human Plasma by an Enzyme‐Linked Immunosorbent Assay Based on Monoclonal Antibodies against a Neoantigen of the Complex , 1985, Scandinavian journal of immunology.

[23]  J. Horrow.  Protamine: A Review of its Toxicity , 1985, Anesthesia and analgesia.

[24]  K. Havemann,et al.  Physiology and pathophysiology of neutral proteinases of human granulocytes. , 1984, Advances in experimental medicine and biology.

[25]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, Thorax.

[26]  R. Larsson,et al.  A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. , 1983, Biomaterials, medical devices, and artificial organs.

[27]  E. Blackstone,et al.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. , 1981, The New England journal of medicine.

[28]  I. Olsson,et al.  Effects of serum and cations on the selective release of granular proteins from human netrophils during phagocytosis. , 2009, Scandinavian journal of haematology.

[29]  R. Dutton,et al.  Heparin Bonding on Colloidal Graphite Surfaces , 1963, Science.